BackPear Therapeutics- Warrants (01/12/2026) Overview
Pear Therapeutics Inc - Warrants (01/12/2026)

Pear Therapeutics- Warrants (01/12/2026) Return on Equity

Pear Therapeutics- Warrants (01/12/2026) (PEARW) has a ROE of 81.01%, above the sector sector average of 11.64%.

Get informed when a big investor buys or sells

+ Follow

ROE

81.01%

Return on Equity

81.01%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Pear Therapeutics- Warrants (01/12/2026) (PEARW) FAQ

Pear Therapeutics- Warrants (01/12/2026) (PEARW) currently reports a ROE of 81.01%. That is above the sector sector average of 11.64%. Use the charts on this page to explore Pear Therapeutics- Warrants (01/12/2026)'s ROE history and peer comparisons.

Pear Therapeutics- Warrants (01/12/2026)'s ROE of 81.01% is higher than the its sector sector average of 11.64%. That is roughly 596.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Pear Therapeutics- Warrants (01/12/2026)'s current 81.01% should be judged against industry norms (sector average: 11.64%) and against PEARW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 81.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Pear Therapeutics- Warrants (01/12/2026), and consider following PEARW for alerts when major investors trade the stock.